source
- Ultragenyx's Angelman syndrome drug fails in Phase 3 trial, showing no benefitUltragenyx announced that its experimental therapy GTX-102 for Angelman syndrome did not demonstrate any benefit compared with a sham control in a large Phase 3 trial. The drug had previously show…
- Novartis CAR-T trial deaths spark safety concerns for autoimmune applicationsNovartis disclosed that three participants in its CAR-T cell therapy trials for autoimmune disease have died. The company said the deaths were reported to health authorities and are under investiga…